Panel: Biotech Industry Executives Shine Light On Their IP Management Strategies

Speakers at the biotech industry side event at WIPO

“IP is a very crucial part of our business and I can’t imagine being in biotech without a very strong emphasis on intellectual property,” a biotech industry executive said during a panel organised at the World Intellectual Property Organization yesterday.

South Africa Draft Copyright Amendment Bill Published For Public Comment

south_africa_cape_town_table_mountain_12

The publication for public comment of the much-anticipated South African draft Copyright Amendment Bill has cautiously been welcomed by some stakeholders, who believe that parts of the draft are unworkable.

Ukraine Open Access Initiative Roils Local Authors Seeking Copyright Protection

Vladimir Groisman, head of Ukraine's Verkhovna Rada and an author of the new initiative

It may be an open access initiative, but Ukrainian writers and authors are on the verge of massive protests, due to a recent initiative of the Ukrainian Parliament (Verkhovna Rada) to conduct digitalisation and online publishing of all of the books and documents stored in the national archives and libraries.

Decision Time On Biologics Exclusivity: Eight Years Is No Compromise

tppBanner

Burcu Kilic and Courtney Pine write: As the Trans-Pacific Partnership (TPP) negotiations approach their endgame, biologics exclusivity is still considered “one of the most difficult outstanding issues in the negotiation.”[2] Pharmaceutical companies seek longer data and marketing exclusivities to further delay market entry of cost-saving biosimilar drugs. Data exclusivity prevents follow-on pharmaceutical developers from relying on originators’ test data submitted for marketing approval while seeking such approval for its own product. The World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) requires some protection against unfair competition for this sort of data, but it does not require countries to adopt rules conveying exclusive rights over it in the same way as it does regarding patents.[3] Currently, the US provides 12 years of exclusivity for new biological products under the Biologics Price Competition and Innovation Act (BPCIA).[4] The provision providing 12 years exclusivity was buried inside the 20,000-page healthcare law, The Patient Protection and Affordable Care Act. A robust debate over what would be an appropriate exclusivity period, if any, was overshadowed by other controversial aspects of the bill commonly referred to as Obamacare.

Intellectual Property Law Under The Prism Of The Right To Culture

ceipi logo

STRASBOURG, FRANCE – Although the right to science and culture has been enshrined in several international treaties, their exact implications in the intellectual property field have remained vague.

Is The European Unitary Patent System On Its Way To A Tepid Start?

EPO President Benoit Battistelli

For nearly two decades, the European Union has pondered the completion of a unitary patent system (UP) and a Unitary Patent Court (UPC). But even after the European Court of Justice has ruled the UP/UPC agreement to be constitutional, users, including some big ones, remain cautious.

UNCTAD Official: Need For Policy Coherence In Local Pharmaceutical Production

medicines-flickr

Despite progress in recent years to boost local pharmaceutical production in developing countries, policy coherence across the countries is lacking, according to an official at the United Nations Conference on Trade and Development (UNCTAD).

Defendants, Non-Profits, Defensive Aggregators And Hedge Funds: Common And Less Common Uses Of Inter Partes Review

Richard Hung,
Photo ©John Swanda 2013

Inter partes review (“IPR”) proceedings were originally intended to allow defendants in patent infringement lawsuits to invalidate questionable patents cheaply and quickly. But these proceedings increasingly are being used by parties that are not defendants in active litigation matters at all, write Rich Hung and Alex Hadduck.

A Geneva Look At Jurisdiction, Dispute Resolution And The Internet

UNIGE summer internet law - Mar 2015.jpg

A conference on jurisdiction and dispute resolution in the age of the internet raised topical issues of concern to internet-based public policy, such as the notion of how jurisdiction and internet governance is a question of power, and an update on the International Law Association guidelines project. In addition, a debate arose as to the state of the patent system.

Learning From Ebola

15_square_ebola

In 1976, Yambuku village school headmaster Mabalo Lokela felt sick when he returned from a trip to northern Zaire near the Central African Republic border. He had a high fever, diarrhea, and bleeding. Because he was initially believed to have malaria, Lokela was given quinine, but his symptoms got worse and he soon died. Shortly afterwards, those who had been in contact with Lokela also died. … Almost four decades later, there is still no cure for Ebola, despite the fact that drug development on average takes about a third of this time frame, write William Fisher and Quentin Palfrey.